Table 2 Enasidenib-related adverse events reported in ≥10% of patients

From: Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Adverse event Patients with newly diagnosed AML N = 39
All grades Grade ≥3
n (%)
Hyperbilirubinemia 12 (31) 5 (13)
Nausea 9 (23) 0
Decreased appetite 7 (18) 1 (3)
Fatigue 7 (18) 1 (3)
Thrombocytopenia 7 (18) 3 (8)
Rash 7 (18) 0
Anemia 6 (15) 5 (13)
IDH differentiation syndrome 5 (13) 4 (10)a
Dysgeusia 4 (10) 0
Electrocardiogram QT prolongation 4 (10) 1 (3)
Peripheral neuropathy 4 (10) 0
Tumor lysis syndrome 4 (10) 3 (8)
Vomiting 4 (10) 0